Biogen Idec Ma Inc.

Biogen Idec, Inc.

Seikagaku Corporation

Idec Pharmaceuticals Corporation

William S Kloetzer

Mitchell E Reff

Takehiko Nakamura

Nabil Hanna

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.

Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics

Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.

The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and/or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.

Method for preparing anti-MIF antibodies

&#x3b3;-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics

Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains.

Growing community of inventors

Carlsbad, CA, United States of America

William S Kloetzer